Cancer Research UK trial shows improved 5 year survival for pancreatic cancer patients

Cancer Research UK

AN extra 13 percent of pancreatic cancer patients will live for at least five years when given a combination of chemotherapy drugs compared with standard treatment, according to the results of a Cancer Research UK trial* being presented at the American Society of Clinical Oncology (ASCO).

"The difference in short term survival may seem modest, but improvement in long-term survival is substantial for this cancer." - Professor John Neoptolemos, University of Liverpool

Researchers working on the major pancreatic clinical trial say this combination treatment should be the new standard of care for patients with the disease.

Doctors on the trial, taking place in many hospitals across the UK, Germany, Sweden and France, treated 732 patients who had surgery to remove their tumour. Around half of them received the chemotherapy drug gemcitabine, the standard treatment for pancreatic cancer, and the other half received a combination of gemcitabine and capecitabine.

The trial showed that 29 per cent of patients given the drug combination lived at least five years compared with only 16 per cent of patients given gemcitabine alone.

There was no significant difference in side effects** between the patients on the standard treatment and the combination treatment.

This trial was set up in 2008 to address the poor pancreatic cancer survival rates.

The latest Cancer Research UK figures show that around 9,400 people are diagnosed with pancreatic cancer each year in the UK and around 8,800 people die*** from the disease each year.

Trial lead, Professor John Neoptolemos at the University of Liverpool, said: “This important trial shows that this drug combination could give pancreatic patients valuable extra months and even years and so will become the new treatment for patients with this disease.

“The difference in short term survival may seem modest, but improvement in long-term survival is substantial for this cancer.

“Although pancreatic cancer is difficult to treat, finding drugs that will shrink the tumour enough to make it suitable for surgery will help in the fight against this disease. We’ve learnt a lot about pancreatic cancer from our clinical trials and now this drug combination will become the new standard of care for patients with the disease.”

Professor Peter Johnson, Cancer Research UK’s chief clinician, said: “Nearly 10 000 people are diagnosed with pancreatic cancer each year in the UK and it remains a very difficult disease to find and treat. Despite this we are making steady progress, through trials like this one, where the use of better chemotherapy after surgery was able to increase the number of people surviving the disease.   We still have a long way to go, but Cancer Research UK is investing heavily into research to take on pancreatic cancer, and we are just starting to see the results.” 

ENDS

For media enquiries please contact the Cancer Research UK press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059. 

Notes to Editor

ESPAC-4

** Side effects include a drop in blood cells causing an increased risk of infection, bleeding or bruising problems, tiredness or shortness of breath, sore mouth, diarrhoea, feeling sick or being sick, sore hands and feet, flu like symptoms.

*** Pancreatic cancer is the fifth most common cause of cancer death in the UK.